Stephen Friend Berlin9 2011-11-10

  • 192 views
Uploaded on

Stephen Friend, Nov 10, 2011. Berlin9, Washington, DC

Stephen Friend, Nov 10, 2011. Berlin9, Washington, DC

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
192
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
2
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. gd oi Nw nn o e ae w
  • 2. Reality: Overlapping Pathways
  • 3. The value of appropriate representations/ maps
  • 4. WHY  NOT  USE     “DATA  INTENSIVE”  SCIENCE  TO  BUILD  BETTER  DISEASE  MAPS?  
  • 5. what will it take to understand disease?                    DNA    RNA  PROTEIN  (dark  maHer)    MOVING  BEYOND  ALTERED  COMPONENT  LISTS  
  • 6. 2002 Can one build a “causal” model?
  • 7. (Eric Schadt)
  • 8. We still consider much clinical research as if we we hunter gathers! not sharing - .
  • 9. Clinical/genomic data are accessible but minimally usableLittle incentive to annotate and curate data for other scientists to use
  • 10. Mathematicalmodels of disease are not built to be reproduced orversioned by others
  • 11. Assumption that genetic alterationsin human conditions should be owned
  • 12. Lack of standard forms for future rights and consentss
  • 13. sharing as an adoption of common standards.. Clinical Genomics Privacy IP
  • 14. Publication Bias- Where can we find the (negative) clinical data?
  • 15. Sage Mission Sage Bionetworks is a non-profit organization with a vision to create a commons where integrative bionetworks are evolved by contributor scientists with a shared vision to accelerate the elimination of human diseaseBuilding Disease Maps Data RepositoryCommons Pilots Discovery Platform Sagebase.org
  • 16. Sage Bionetworks Collaborators  Pharma Partners   Merck, Pfizer, Takeda, Astra Zeneca, Amgen, Johnson &Johnson  Foundations   Kauffman CHDI, Gates Foundation  Government   NIH, LSDF  Academic   Levy (Framingham)   Rosengren (Lund)   Krauss (CHORI)  Federation   Ideker, Califarno, Butte, Schadt 19
  • 17. sage bionetworks synapse project Watch What I Do, Not What I Say Reduce, Reuse, Recycle My Other Computer is Amazon Most of the People You Need to Work with Don’t Work with You
  • 18. M e ogn g ow gd oi Nnoi g e e own wgi A M S FOR MAP i   ow PLAT ow i nn i o g EW N RULES GOVERN
  • 19. CTCAP  Clinical Trial Comparator Arm Partnership “CTCAP”Strategic Opportunities For Regulatory Science Leadership and Action FDA September 27, 2011
  • 20. Shared clinical/genomic data sharing and analysis will maximize clinical impact and enable discovery•  Graphic  of  curated  to  qced  to  models  
  • 21. Arch2POCM  Restructuring  the  PrecompePPve   Space  for  Drug  Discovery   How  to  potenPally  De-­‐Risk       High-­‐Risk  TherapeuPc  Areas  
  • 22. The  FederaPon  
  • 23. sage federation:model of biological age Faster Aging U M i l r i nnowS Slower Aging e Clinical Association -  Gender -  BMI g -  Disease Age Differential Genotype Association Gene Pathway Expression i i owoe o e U i nS B
  • 24. Sage  Congress  Project   April  20  2012   RA   Parkinson’s   Asthma  (Responders  CompePPons)  
  • 25. Actionable Cancer Network ModelsAnd Open Medical Information Systems